Schizophrenia Management

Diagnosis and Symptoms

• Negative symptoms in schizophrenia can be categorized into two factors: experiential (avolition, anhedonia, asociality) and expressive (blunted affect, alogia), related to motivational deficits and cognition, respectively, in patients with schizophrenia 1
• Negative symptoms are present in up to 90% of first-episode psychosis patients and persist in 35-70% of patients after treatment, highlighting the need for comprehensive diagnosis and treatment planning 1
• Medical causes of psychotic symptoms, such as intoxication, delirium, CNS lesions, metabolic disorders, and seizure disorders, should be ruled out in the differential diagnosis of schizophrenia to ensure accurate diagnosis and treatment 2
• Psychotic mood disorders, developmental disorders, and substance-induced psychosis should be considered in the differential diagnosis of schizophrenia to differentiate it from other conditions with similar symptoms 2

Treatment

• Treatment-resistant schizophrenia is defined as inadequate response to ≥2 different antipsychotic trials of adequate duration and dose, with specific criteria including current symptoms of minimum duration and severity, moderate or greater functional impairment, prior treatment with ≥2 different antipsychotics at adequate dose and duration, and systematically assessed adherence, affecting up to 30% of patients 3
• Antipsychotic medications are recommended as the first-line treatment for schizophrenia, with atypical antipsychotics preferred due to better efficacy for both positive and negative symptoms, as recommended by the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry 4, 2
• Antipsychotic monotherapy is strongly recommended as first-line treatment, with initiation for individuals experiencing psychotic symptoms for ≥1 week with distress or functional impairment, and trials should be at least 4-6 weeks before determining efficacy, as recommended by the American Psychiatric Association and the National Institute of Mental Health 4, 5
• Clozapine is recommended after two failed antipsychotic trials for treatment-resistant schizophrenia, as suggested by the American Psychiatric Association and the National Alliance on Mental Illness 4
• The following treatment approaches are recommended:

Special Populations and Treatment Considerations

• Early-onset schizophrenia is often associated with male predominance, high rates of premorbid abnormalities, and poor outcomes, and increased family history of schizophrenia and schizophrenia spectrum disorders is a risk factor for the development of schizophrenia, as suggested by the American Academy of Child and Adolescent Psychiatry 2
• Psychosocial stressors can influence the onset or exacerbation of acute episodes of schizophrenia, according to the American Academy of Child and Adolescent Psychiatry 2
• The prodromal, acute, recuperative/recovery, and residual phases of schizophrenia have distinct characteristics, including social withdrawal, positive symptoms, negative symptoms, and prolonged impairment, as described by the American Academy of Child and Adolescent Psychiatry 2
• Cognitive-behavioral therapy for psychosis (CBTp), psychoeducation, supported employment services, assertive community treatment, and family interventions should be implemented concurrently with medication to improve functional outcomes, as recommended by the American Psychiatric Association 4
• Regular monitoring of weight, blood glucose, and lipids is recommended to manage metabolic effects, and assessment for extrapyramidal symptoms should be conducted, according to the American Psychiatric Association 4
• Ongoing evaluation of both psychotic and mood symptoms should be performed, and quantitative measurement of symptom severity should be used to track treatment response, as suggested by the American Psychiatric Association 4
• Side effects such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia should be managed with specific treatments, including anticholinergic medication, dose adjustment, and VMAT2 inhibitors, as recommended by the American Psychiatric Association 4
• Metabolic side effects should be managed by considering switching to an antipsychotic with a better metabolic profile, adding metformin for weight management, and implementing lifestyle interventions, according to the American Psychiatric Association 4
• Antipsychotic polypharmacy is not generally recommended as a first-line approach and may increase side effects without clear benefit, according to the American Psychiatric Association and the American Medical Association 5
• Long-acting injectable (LAI) antipsychotics are recommended for patients who prefer such treatment and for patients with a history of poor or uncertain adherence, as recommended by the American Psychiatric Association and the British Psychiatric Association 4, 6